Alzheimer’s disease affects more than 50 million people worldwide and this number is expected to increase in low and middle-income countries. It is a disease that begins decades before the symptoms become manifest. The signs of this pathology within the brain are detectable thanks to neuroimaging and fluid biomarkers. It is important to detect such signs before cognitive decline appears such as disease-modifying treatments can act before the damage is too advanced and irreversible. This is why Roche is working really hard to bring a real transformative solution to the way we manage this disease by introducing reliable CSF biomarkers to detect amyloid pathology, a hallmark of the disease, into the market and developing even novel ones to better characterize the pathology and patients characteristics. This will improve not only patient management but also clinical trial design and therefore clinical outcomes. At the same time, Roche is developing disease-modifying treatments which are a must if we want to defeat the last challenges and unmet needs in medicine, where even people like Bill Gates, decided to join the floor and defeat these conditions for which today we have no cure.
Being a pathologist, a neuroscientist who worked for years to find an immunotherapy for Alzheimer's disease and more importantly a doctor who spent years in a locked ward with people living with this devastating condition, it is a privilege for me to be within the Roche community in achieving the goal of making Alzheimer's disease a curable disease hopefully soon.
The place to Work
My work at Roche allows me to pursue my passion. Roche represents for me a unique platform to bring my medical and scientific competence at the disposal of the entire Alzheimer’s disease ecosystem and where patients are at the center.
In fact, I have decades of professional experience in Alzheimer’s disease. I have not only worked as a neuroscientist for the development of immunotherapy to treat this devastating condition, but I have also managed patients living with this disease. Being at Roche Pharma and Roche Diagnostic in medical affairs, allows me to apply all this precious learning for the amelioration of the diagnostic and therapeutic solutions for Alzheimer's disease on a global scale.
Roche allows the freedom to implement our ideas for the benefit of the organization but above all for the benefit of the patients. It is not by chance that Roche is supporting the Women's Brain Project work as well.
My workplace at Roche is the world, in fact. In a global position like mine between Roche Pharma and Roche Diagnostics in medical affairs, I work in several places all over the world. This allows me to be flexible and this is what I need being a working mother as well as a citizen of a world transforming every day. But also to deliver on global outcomes as the work follows me and not the other way around.